X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3686) 3686
Publication (602) 602
Newsletter (170) 170
Newspaper Article (27) 27
Book Chapter (24) 24
Book Review (16) 16
Conference Proceeding (12) 12
Magazine Article (10) 10
Dissertation (4) 4
Trade Publication Article (3) 3
Paper (2) 2
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (3425) 3425
humans (2452) 2452
index medicus (2188) 2188
oncology (1403) 1403
imatinib (1103) 1103
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1006) 1006
hematology (988) 988
chronic myeloid leukemia (894) 894
female (891) 891
male (867) 867
imatinib mesylate (851) 851
nilotinib (828) 828
pyrimidines - therapeutic use (827) 827
protein kinase inhibitors - therapeutic use (816) 816
chronic myelogenous leukemia (784) 784
chronic myeloid-leukemia (710) 710
middle aged (692) 692
antineoplastic agents - therapeutic use (671) 671
cancer (668) 668
thiazoles - therapeutic use (630) 630
protein kinase inhibitors - pharmacology (604) 604
adult (597) 597
pyrimidines - pharmacology (597) 597
animals (583) 583
aged (562) 562
leukemia (544) 544
benzamides (536) 536
research (517) 517
hemic and lymphatic diseases (467) 467
thiazoles - pharmacology (467) 467
cell line, tumor (458) 458
tyrosine (455) 455
treatment outcome (443) 443
bcr-abl (434) 434
care and treatment (427) 427
piperazines - therapeutic use (425) 425
therapy (414) 414
tyrosine kinase inhibitors (413) 413
protein-tyrosine kinases - antagonists & inhibitors (406) 406
mutation (391) 391
tyrosine kinase inhibitor (390) 390
mice (385) 385
antineoplastic agents - pharmacology (369) 369
pyrimidines - adverse effects (353) 353
drug therapy (338) 338
pyrimidines - administration & dosage (323) 323
drug resistance, neoplasm (319) 319
leukemia, myelogenous, chronic, bcr-abl positive - genetics (316) 316
resistance (314) 314
fusion proteins, bcr-abl - genetics (313) 313
article (312) 312
pharmacology & pharmacy (311) 311
protein kinase inhibitors - adverse effects (305) 305
cml (299) 299
analysis (294) 294
kinases (281) 281
follow-up (275) 275
tyrosine kinase (269) 269
protein kinase inhibitors - administration & dosage (262) 262
chronic-phase (259) 259
aged, 80 and over (256) 256
thiazoles - adverse effects (249) 249
activation (245) 245
thiazoles - administration & dosage (245) 245
chemotherapy (244) 244
antineoplastic agents - adverse effects (241) 241
dosage and administration (237) 237
health aspects (237) 237
phosphorylation (236) 236
leukemia, myelogenous, chronic, bcr-abl positive - pathology (235) 235
medicine & public health (230) 230
apoptosis (226) 226
hematology, oncology and palliative medicine (225) 225
src-family kinases - antagonists & inhibitors (225) 225
young adult (223) 223
antineoplastic agents (222) 222
fusion proteins, bcr-abl - antagonists & inhibitors (220) 220
dasatinib - therapeutic use (215) 215
cell proliferation - drug effects (213) 213
src (212) 212
src-family kinases - metabolism (210) 210
expression (209) 209
genetic aspects (208) 208
apoptosis - drug effects (207) 207
in-vitro (206) 206
cytogenetic responses (203) 203
piperazines - pharmacology (200) 200
philadelphia chromosome (197) 197
cell biology (194) 194
antimitotic agents (193) 193
abridged index medicus (192) 192
antineoplastic agents - administration & dosage (192) 192
kinase inhibitor (190) 190
cells (189) 189
dasatinib - pharmacology (189) 189
imatinib-resistant (188) 188
signal transduction - drug effects (185) 185
antineoplastic combined chemotherapy protocols - therapeutic use (184) 184
protein-tyrosine kinase (184) 184
adolescent (175) 175
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3690) 3690
Japanese (51) 51
Chinese (29) 29
French (27) 27
Polish (24) 24
Russian (22) 22
Spanish (17) 17
German (14) 14
Czech (9) 9
Korean (9) 9
Portuguese (6) 6
Turkish (6) 6
Danish (2) 2
Hebrew (2) 2
Italian (2) 2
Slovenian (2) 2
Finnish (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5915 - 5915
Abstract Introduction Survival outcomes for patients with lymphoid, myeloid and plasma cell malignancies, have improved with the use of oral small molecule... 
Journal Article
Biosensors and Bioelectronics, ISSN 0956-5663, 12/2016, Volume 86, pp. 879 - 884
Journal Article
Journal Article
Journal Article
Science, ISSN 0036-8075, 07/2019, Volume 365, Issue 6448, p. 41
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 611 - 613
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) criteria for discontinuation of tyrosine kinase inhibitor (TKI) therapy have not seen significant... 
ONCOLOGY | IMATINIB | DASATINIB
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 6, pp. 868 - 874
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 43 - 55
Two novel prodrug polymers POEG- -PSSDas (redox-sensitive) and POEG- -PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate)... 
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | DESIGN | DRUG-DELIVERY | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | CHRONIC MYELOID-LEUKEMIA | PACLITAXEL | BREAST-CANCER CELLS | FAMILY KINASE INHIBITOR | IMATINIB | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1568 - 1571
Journal Article
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
BACKGROUND The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 5
Journal Article
Cancer, ISSN 0008-543X, 11/2015, Volume 121, Issue 21, pp. 3894 - 3904
BACKGROUND Chronic use of tyrosine kinase inhibitors (TKIs) may lead to previously unrecognized adverse events. This study evaluated the incidence of acute... 
dasatinib | nilotinib | imatinib | glomerular filtration rate changes | tyrosine kinase inhibitor | kidney injury | outcome | chronic myeloid leukemia (CML) | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-FAILURE SECONDARY | TUMOR LYSIS SYNDROME | TUBULAR REGENERATION | ONCOLOGY | PDGF | IMATINIB MESYLATE TREATMENT | IN-VIVO | MESANGIAL CELLS | GROWTH-FACTOR | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Protein Kinase Inhibitors - adverse effects | Glomerular Filtration Rate - physiology | Incidence | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - epidemiology | Young Adult | Creatinine - metabolism | Glomerular Filtration Rate - drug effects | Imatinib Mesylate - therapeutic use | Kidney - metabolism | Imatinib Mesylate - adverse effects | Aged, 80 and over | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Kidney - physiopathology | Kidney - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Imatinib Mesylate - pharmacology | Dasatinib - therapeutic use | Treatment Outcome | Pyrimidines - pharmacology | Dasatinib - pharmacology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Acute Kidney Injury - epidemiology | Renal Insufficiency, Chronic - chemically induced | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Dasatinib | Care and treatment | Myelocytic leukemia | Analysis | Dosage and administration | Nonlymphoid leukemia | Diagnosis | Glomerular filtration rate
Journal Article